SOLÁR, Peter, Zdeněk MACKERLE, Marek JOUKAL and Radim JANČÁLEK. Non-steroidal anti-inflammatory drugs in the pathophysiology of vasospasms and delayed cerebral ischemia following subarachnoid hemorrhage: a critical review. NEUROSURGICAL REVIEW. NEW YORK: SPRINGER, 2021, vol. 44, No 2, p. 649-658. ISSN 0344-5607. Available from: https://dx.doi.org/10.1007/s10143-020-01276-5.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Non-steroidal anti-inflammatory drugs in the pathophysiology of vasospasms and delayed cerebral ischemia following subarachnoid hemorrhage: a critical review
Authors SOLÁR, Peter (703 Slovakia, belonging to the institution), Zdeněk MACKERLE (203 Czech Republic, belonging to the institution), Marek JOUKAL (203 Czech Republic, belonging to the institution) and Radim JANČÁLEK (203 Czech Republic, guarantor, belonging to the institution).
Edition NEUROSURGICAL REVIEW, NEW YORK, SPRINGER, 2021, 0344-5607.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.800
RIV identification code RIV/00216224:14110/21:00120663
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s10143-020-01276-5
UT WoS 000517727800002
Keywords in English Aneurysmal subarachnoid hemorrhage; Non-steroidal anti-inflammatory drugs; Vasospasms; Cerebral ischemia
Tags 14110131, 14110514, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/6/2021 14:13.
Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition associated with the development of early brain injury (EBI) and delayed cerebral ischemia (DCI). Pharmacological treatment of vasospasm following aSAH currently mainly comprises nimodipine administration. In the past few years, many drugs that can potentially benefit cases of subarachnoid hemorrhage have become available. The objective of this review is to critically assess the effects of non-steroidal anti-inflammatory drugs (NSAIDs) following aSAH. A systematic literature review was conducted following PRISMA guidelines. The search was aimed at studies addressing aSAH and NSAIDs during the 2010 to 2019 period, and it yielded 13 articles. Following the application of search criteria, they were divided into two groups, one containing 6 clinical articles and the other containing 7 experimental articles on animal models of aSAH. Inflammatory cerebral changes after aneurysm rupture contribute to the development of EBI, DCI and cerebral vasospasm. It appears that NSAIDs (especially coxibs) are even more effective in reducing vasospasm than nimodipine. Other beneficial effects of NSAIDs include reduction in mortality, improved functional outcome and increased hypoaggregability. However, despite these positive effects, there is only one randomized, double-blind, placebo-controlled trial showing a tendency towards a better outcome with lower incidence of vasospasm or mortality in patients following aSAH.
PrintDisplayed: 3/5/2024 23:46